Defence Receives No Objection Letter From Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients With Melanoma

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company develop

newsfileJul 8 03:15 ET

Defence's AccuTOX Boosts and Synergizes With Immune Checkpoint Inhibitors

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company develo

newsfileJun 28 17:08 ET

Defence's ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company develo

newsfileJun 25 03:15 ET

Defence's Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio With Ellis Martin

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company develo

newsfileJun 17 03:15 ET

Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024

Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company devel

newsfileJun 10 03:15 ET

Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study With Preclinical Data on AccuTOX as an Anti-Cancer Molecule

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company develo

newsfileJun 6 03:15 ET